Aileron Therapeutics Announces CEO Transition and Board Update
Company Announcements

Aileron Therapeutics Announces CEO Transition and Board Update

Aileron Therapeutics Inc (ALRN) has provided an update.

Aileron Therapeutics, Inc. announced that Dr. Manuel C. Alves-Aivado stepped down as CEO on March 11, 2024, but will continue to serve on the Board. His departure was amicable, with no disagreements cited. Dr. Brian Windsor was appointed as the new CEO and also joined the Board, bringing extensive experience from previous leadership roles in biopharmaceutical companies. Dr. Aivado will receive severance benefits, including extended salary and medical insurance coverage, as per his 2018 agreement with the company.

For detailed information about ALRN stock, go to TipRanks’ Stock Analysis page.

Related Articles
PR NewswireAileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
TheFlyAileron Therapeutics reports Q2 EPS (45c), one estimate (42c)
TheFlyAileron Therapeutics to be included in Russell Microcap Index
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App